Bulletin du cancer · 2026
[General practitioners' knowledge of anticancer immunotherapies and their adverse effects: A cross-sectional survey].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guigue François, Pacoureau Lucas, Placais Leo, Coindard Guillaume, Lambotte Olivier
Аннотация
INTRODUCTION: Cancer remains the leading cause of mortality in France. The rise of anticancer immunotherapies improves patient prognosis but carries a risk of immune-related adverse events. The increasing role of general practitioners in patient follow-up raises questions about their knowledge and confidence in managing these effects.
METHODS: A cross-sectional survey was conducted among general practitioners identified through the REISAMIC registry at the Institut Gustave Roussy. A questionnaire assessing knowledge of immunotherapies, familiarity with adverse effects, and clinical experience was mailed between October 2019 and November 2020. Responses were analyzed according to practice setting (urban/rural), type of practice (alone/in group) and year of installation.
RESULTS: Among 507 questionnaires sent, 136 responses were collected. Most general practitioners (80 %) rated their knowledge of immunotherapies and their adverse effects as insufficient. More than 90 % had already managed at least one patient treated with immunotherapy, and 38 % had handled an adverse effect. Nearly 40 % reported being "not at all comfortable" with this management. Differences according to year of installation and practice setting were minimal. Almost all participants (96 %) wished to receive additional information on these treatments.
DISCUSSION: These findings reveal a deficit in knowledge and confidence among general practitioners exposed to anticancer immunotherapies. Although collected in 2019-2020, these data provide a reference baseline at a pivotal period, prior to major evolutions in the digital medical ecosystem. They emphasize the need for targeted training and improved hospital-community coordination to secure patient management and strengthen confidence among healthcare professionals and patients.
METHODS: A cross-sectional survey was conducted among general practitioners identified through the REISAMIC registry at the Institut Gustave Roussy. A questionnaire assessing knowledge of immunotherapies, familiarity with adverse effects, and clinical experience was mailed between October 2019 and November 2020. Responses were analyzed according to practice setting (urban/rural), type of practice (alone/in group) and year of installation.
RESULTS: Among 507 questionnaires sent, 136 responses were collected. Most general practitioners (80 %) rated their knowledge of immunotherapies and their adverse effects as insufficient. More than 90 % had already managed at least one patient treated with immunotherapy, and 38 % had handled an adverse effect. Nearly 40 % reported being "not at all comfortable" with this management. Differences according to year of installation and practice setting were minimal. Almost all participants (96 %) wished to receive additional information on these treatments.
DISCUSSION: These findings reveal a deficit in knowledge and confidence among general practitioners exposed to anticancer immunotherapies. Although collected in 2019-2020, these data provide a reference baseline at a pivotal period, prior to major evolutions in the digital medical ecosystem. They emphasize the need for targeted training and improved hospital-community coordination to secure patient management and strengthen confidence among healthcare professionals and patients.